Want to see NL:VVY full AI Analyst Report?
VVY Stock Chart & Stats
€1.18
€0.02(1.27%)
At close: 4:00 PM EDT
€1.18
€0.02(1.27%)
Day’s Range― - ―
52-Week Range€1.00 - €1.84
Previous CloseN/A
Volume2.70K
Average Volume (3M)31.39K
Market Cap
€35.39M
Enterprise Value€35.14
Total Cash (Recent Filing)€5.62M
Total Debt (Recent Filing)€108.00K
Price to Earnings (P/E)―
Beta0.66
Next Earnings
Aug 06, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.33
Shares Outstanding29,614,338
10 Day Avg. Volume27,146
30 Day Avg. Volume31,394
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)8.11
Price to Sales (P/S)0.00
P/FCF Ratio-4.53
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.38
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageVery low reported debt (debt-to-equity ~0.02 in 2025) provides a durable financial buffer. Low leverage reduces near-term solvency risk and preserves flexibility to prioritize R&D or pursue partnerships rather than servicing debt, a lasting structural advantage during clinical development.
Improving Cash Burn TrendMaterial improvement in 2025 operating cash outflow versus 2024 signals effective cost control or program prioritization. If sustained, lower cash burn extends runway, enabling continued clinical progress and more attractive partnership timing, a durable operational improvement for a pre-revenue biotech.
Focused Small-molecule PlatformA clear R&D focus on orally available small-molecule therapeutics and a lead Alzheimer’s candidate concentrates scarce resources on high-impact assets. This specialized platform increases the odds of forming strategic collaborations or licensing deals, a persistent business-model strength for clinical-stage firms.
Bears Say
No Recent RevenueAbsence of product or recurring revenue and persistent net losses mean the company cannot internally fund operations. Over months this creates structural dependence on financing, raising dilution and execution risk for clinical programs and limiting self-sustained growth prospects.
Eroding Equity And AssetsSharp decline in equity and total assets over two years materially reduces financial flexibility and bargaining power with partners. This structural erosion heightens solvency and funding risks, constraining options for non-dilutive financing and increasing vulnerability if cash burn continues.
Persistent Negative Cash FlowConsistently negative operating and free cash flow creates a continuing funding gap that necessitates external capital. Reliance on equity or sporadic partner payments is a structural weakness that can delay programs, dilute shareholders, and limit strategic autonomy over the medium term.
Vivoryon Therapeutics AG News
VVY FAQ
What was Vivoryon Therapeutics AG’s price range in the past 12 months?
Vivoryon Therapeutics AG lowest stock price was €1.00 and its highest was €1.84 in the past 12 months.
What is Vivoryon Therapeutics AG’s market cap?
Vivoryon Therapeutics AG’s market cap is €35.39M.
When is Vivoryon Therapeutics AG’s upcoming earnings report date?
Vivoryon Therapeutics AG’s upcoming earnings report date is Aug 06, 2026 which is in 3 days.
How were Vivoryon Therapeutics AG’s earnings last quarter?
Currently, no data Available
Is Vivoryon Therapeutics AG overvalued?
According to Wall Street analysts Vivoryon Therapeutics AG’s price is currently Overvalued.
Does Vivoryon Therapeutics AG pay dividends?
Vivoryon Therapeutics AG does not currently pay dividends.
What is Vivoryon Therapeutics AG’s EPS estimate?
Vivoryon Therapeutics AG’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Vivoryon Therapeutics AG have?
Vivoryon Therapeutics AG has 29,614,338 shares outstanding.
What happened to Vivoryon Therapeutics AG’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Vivoryon Therapeutics AG?
Currently, no hedge funds are holding shares in NL:VVY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Vivoryon Therapeutics AG
Vivoryon Therapeutics N.V. is a clinical-stage biopharmaceutical firm dedicated to discovering and developing novel treatments for Alzheimer's disease. The company's therapeutic pipeline primarily focuses on mitigating Alzheimer's by targeting and preventing the formation of toxic pyroglutamate-Abeta (pGlu-Abeta). Its flagship compound, PQ912, a small molecule QC inhibitor, has successfully concluded Phase IIb clinical trials for both Alzheimer's disease and various cancer indications. Additionally, Vivoryon is advancing PQ1565, another small molecule (a glutaminyl-peptide cyclotransferase-like inhibitor), through preclinical development, specifically for cancer therapy. Beyond its small molecule programs, the company is also developing a monoclonal antibody designed to improve the clearance of pGlu-Abeta from the body. To bolster its research and development efforts, Vivoryon has forged several key partnerships, including collaborations with the University Medical Center Schleswig-Holstein for cancer immunotherapy discovery, Nordic Bioscience for the clinical progression of PQ912 in Alzheimer's, and the Fraunhofer Institute for cell therapy and immunology. Furthermore, a significant regional licensing agreement with Simcere Pharmaceutical Group Ltd. aims to develop and commercialize treatments for Alzheimer's disease by targeting the neurotoxic amyloid species N3pE (pGlu-Abeta). Established in 1997, Vivoryon Therapeutics N.V. maintains its headquarters in Halle, Germany.